Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CKSWS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Sonesitatug vedotin
|
|||||
| Synonyms |
sonesitatug vedotin; CMG901; AZD0901; KYM901
Click to Show/Hide
|
|||||
| Organization |
Miracogen (Originator);AstraZeneca (Top20 MNC);Keymed Biosciences
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Sonesitatug
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
||||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
2 Trials
|
1 Trials
|
||||||||
| Gastric cancer |
1 Trials
|
2 Trials
|
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||||
| Biliary tract cancer |
1 Trials
|
2027 Update
ADC-specific functional property
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 2.44 nM |
KATOIII-hCLDN18.2
|
To assess the ADC's binding activity and specificity, we investigated the binding of CMG901 to cell lines KATOIII-hCLDN18.2, HEK293-hCLDN18.2, and HEK293-hCLDN18.1 using flow cytometry. CMG901 bound specifically to KATOIII-hCLDN18.2 and HEK293-hCLDN18.2 in a concentration-dependent manner with high affinity (half maximum effective concentration [EC50] = 2.44 to 6.43 nM)
Click to Show/Hide
|
[1]
|
| 6.43 nM |
HEK293-hCLDN18.2
|
To assess the ADC's binding activity and specificity, we investigated the binding of CMG901 to cell lines KATOIII-hCLDN18.2, HEK293-hCLDN18.2, and HEK293-hCLDN18.1 using flow cytometry. CMG901 bound specifically to KATOIII-hCLDN18.2 and HEK293-hCLDN18.2 in a concentration-dependent manner with high affinity (half maximum effective concentration [EC50] = 2.44 to 6.43 nM)
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
29%
|
|||
| Patients Enrolled |
Eligibility requires ECOG 0-1, advanced solid tumors (Part A: measurable/evaluable; Part B: confirmed Claudin 18.2+ lesions). Key exclusions: recent anticancer therapies (<28 days), active infections/CNS metastases, neuropathy ≥Grade 2, uncontrolled effusions, HBV/HCV viremia, or QTc >480msec. Contraception is mandated for reproductive-age participants.
Click to Show/Hide
|
||||
| Administration Dosage |
CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease (PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04805307 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor | ||||
| Primary Endpoint |
Part A evaluates safety endpoints including AE incidence, lab abnormalities (30 days post-treatment), and MTD determination (21-day DLT window). Part B focuses on preliminary efficacy (ORR per RECIST v1.1) and RP2D establishment for Claudin 18.2+ advanced solid tumors over 24 months.
|
||||
| Other Endpoint |
Comprehensive PK analysis covers AUC (0-last/tau/inf), Cmax, Tmax, clearance, and volume parameters through 24 months, alongside immunogenicity (anti-CMG901 antibodies). Secondary endpoints include DCR, DoR, PFS, OS, and Claudin 18.2 expression correlation, with Part B adding NCI CTCAE v5.0 safety monitoring.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible participants (≥18yo, ECOG 0-1) required CLDN18.2+ lesions (RECIST v1.1), adequate organ function (>35kg). Substudies targeted specific cancers: GC/GEJC (≤2 prior lines), PDAC (treatment-naïve metastatic), biliary tract (1-2 prior lines). Key exclusions: active GI bleeding, ascites, ILD history, CNS metastases, prior MMAE-ADC/CLDN18.2 therapy (except antibodies), QTc risks (Substudy 1), UGT1A1/CYP3A4 interactions (Substudy 2), or biliary obstruction (Substudy 3).
Click to Show/Hide
|
||||
| Administration Dosage |
Substudy 1 is recruiting patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-expressing G/GEJ cancer with ≤2 prior lines of therapy for unresectable or metastatic disease, who are randomized 1:1 to receive AZD0901 1.8 or 2.2 mg/kg intravenous (IV) every 3 weeks (Q3W).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06219941 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) | ||||
| Primary Endpoint |
Safety monitoring included AEs/SAEs, lab/vital sign changes, DLTs (30 days post-treatment; AE follow-up for 90 days). Primary objective assessed AZD0901's safety (monotherapy/combination) in CLDN18.2+ advanced/metastatic solid tumors, analyzing discontinuation rates and tolerability.
|
||||
| Other Endpoint |
Efficacy measures included ORR (RECIST v1.1), OS, PFS (both ~2 years), DoR, DCR (11-week landmark), and tumor shrinkage percentage. PK analysis covered serum concentrations (AZD0901/MMAE) and parameters (AUC/Cmax/tmax) until 90 days post-treatment, alongside immunogenicity (ADA) and biomarker correlations (tissue-based RNA/DNA/proteins) during early treatment.
Click to Show/Hide
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
75%
|
|||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
Day 1 in 3-week (Q3W) cycle 3.40 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04805307 | Clinical Status | Phase 1 | ||
| Clinical Description | An open-label, phase 1, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of CMG901 in subjects with advanced unresectable or metastatic solid tumor. | ||||
References